Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study - Wikidata - wikimedia - TriplyDB

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study

http://www.wikidata.org/entity/Q28608449

about

Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C.HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation

P2860

Q37696844-8981F930-80F1-45C7-B86D-E40C3B15F9FC Q40320642-2BF60C56-1718-4278-865B-9541D7EB0F72 Q51761924-2F3882F2-F05E-4BA5-ADA4-B9967D38876B Q57066911-F0BF83BF-8117-4005-A24F-6BEE7E8B8757

P2860

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study

http://www.wikidata.org/entity/Q28608449

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@ast

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@en

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@nl

type

label

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@ast

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@en

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@nl

prefLabel

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@ast

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@en

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@nl

P1433

Q28608449-3342E68F-77D5-43F9-84C5-7A08C2660C07

P1476

Q28608449-FB098873-F874-4DDA-9282-C9E33C3F6AA1

P2093

Q28608449-1DA19591-FAF7-48EA-AA99-50026619E453

Q28608449-28D7B8DE-0A37-4FEF-B6F4-FDE8D037AD2D

Q28608449-2CA0747C-84BC-40B6-8736-BE1B8A727B9B

Q28608449-422DE375-86F5-49F5-85D8-6BCD4E7F7E6B

Q28608449-432395B7-072F-4565-AAF3-A1528AE93C48

Q28608449-5D1B2622-A31C-4108-9198-EC6E2073B535

Q28608449-5FA05156-DD25-4075-B65D-F9F6D244AA6A

Q28608449-6A426693-7587-4EF8-A149-5E6472C87C86

Q28608449-9434494D-4219-4A21-8CCD-BF1DE8ACCD66

Q28608449-A3A9D139-6A94-47C0-B87D-A96FE26399E5

P2860

Q28608449-031CEF36-AD53-4C35-9ED1-5F89D24EF468

Q28608449-03BC1E7D-D352-42C2-B2BC-7EC5771185C7

Q28608449-0E658DF6-D994-4223-AB7E-E7F5CE32A4BD

Q28608449-14A82C90-0948-400C-B08F-955F7B8118DE

Q28608449-20046AB1-8AB2-4C89-BF6B-895B8B682C23

Q28608449-2EAEBE71-6573-4E1A-A57D-3CBF04585E07

Q28608449-455967AB-C9F9-4F7B-851A-5007228B1BEE

Q28608449-497A028C-057B-468C-975A-05073B6627D1

Q28608449-4AE8E845-273F-4F0B-BC9D-FA0B351F4443

Q28608449-4CE4C035-1A8F-4438-A9B9-906599EB78F2

P304

Q28608449-97BB8F13-FA7F-447D-B94B-F869BE4FFDBC

P31

Q28608449-52413095-0B5B-474F-AD35-6719C457097A

P356

Q28608449-BF51EA74-92B5-4B9B-9706-846656A83EF4

P407

Q28608449-DBB6CDEF-2B5B-4FCB-A8A3-4C4B71869148

P433

Q28608449-F7177ECF-24B0-469B-A082-4E6BEC7E3449

P478

Q28608449-4919ACBD-E062-463A-A6F7-0CFFA794FBF3

P577

Q28608449-6F6CC968-0E0F-4539-AF1E-71E4CCBB9846

P698

Q28608449-EBE65F0E-4A10-475B-810E-FBD533EC5A7D

P932

Q28608449-C458EAA3-C97A-4E43-8677-A3D183DC6702

P356

MD.0000000000001837

P1433

P1476

Personalized Therapy of Chroni ...... Ribavirin: A Randomized Study

@en

P2093

Chia-Yen Dai

http://www.w3.org/2001/XMLSchema#string

Ching-I Huang

http://www.w3.org/2001/XMLSchema#string

Chung-Feng Huang

http://www.w3.org/2001/XMLSchema#string

Jee-Fu Huang

http://www.w3.org/2001/XMLSchema#string

Meng-Hsuan Hsieh

http://www.w3.org/2001/XMLSchema#string

Ming-Lun Yeh

http://www.w3.org/2001/XMLSchema#string

Ming-Lung Yu

http://www.w3.org/2001/XMLSchema#string

Ming-Yen Hsieh

http://www.w3.org/2001/XMLSchema#string

Nai-Jen Hou

http://www.w3.org/2001/XMLSchema#string

Po-Cheng Liang

http://www.w3.org/2001/XMLSchema#string

P2860

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response

Treatment of chronic hepatitis C in Asia: when East meets West.

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

P304

e1837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000001837

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26496327

http://www.w3.org/2001/XMLSchema#string

P932

4620800

http://www.w3.org/2001/XMLSchema#string